Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - amlodipine besilate 6.94mg equivalent to 5.0 mg amlodipine base - tablet - 5 mg - active: amlodipine besilate 6.94mg equivalent to 5.0 mg amlodipine base excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate microcrystalline cellulose sodium starch glycolate - amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - amlodipine besilate 6.94mg equivalent to 5 mg amlodipine;   - tablet - 5 mg - active: amlodipine besilate 6.94mg equivalent to 5 mg amlodipine   excipient: magnesium stearate microcrystalline cellulose sodium starch glycolate starch

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - amlodipine besilate 6.94mg equivalent to amlodipine 5.0 mg - tablet - 5 mg - active: amlodipine besilate 6.94mg equivalent to amlodipine 5.0 mg excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose sodium starch glycolate water

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine;  ; valsartan 160mg;  ;  ;   - film coated tablet - 5mg/160mg - active: amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine   valsartan 160mg       excipient: colloidal silicon dioxide crospovidone coating premix white coating premix yellow magnesium stearate microcrystalline cellulose purified water - exforge is indicated for the treatment of essential hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine;  ; valsartan 80mg;  ;  ;   - film coated tablet - 5mg/80mg - active: amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine   valsartan 80mg       excipient: colloidal silicon dioxide crospovidone coating premix white coating premix yellow magnesium stearate microcrystalline cellulose purified water - exforge is indicated for the treatment of essential hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amlodipine besilate 14mg equivalent to to 10 mg amlodipine;   - tablet - 10 mg - active: amlodipine besilate 14mg equivalent to to 10 mg amlodipine   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amlodipine besilate 3.5mg equivalent to 2.5 mg amlodipine;   - tablet - 2.5 mg - active: amlodipine besilate 3.5mg equivalent to 2.5 mg amlodipine   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amlodipine besilate 7mg equivalent to to 5 mg amlodipine;   - tablet - 5 mg - active: amlodipine besilate 7mg equivalent to to 5 mg amlodipine   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.